Unprovoked venous thromboembolism (VTE) can be the first manifestation of an undiagnosed cancer. Recently published studies have suggested that approximately 4-5% of patients with new unprovoked VTE will be diagnosed with cancer within 12 months of follow-up. Therefore, it is important for clinicians to keep a low threshold of suspicion for occult cancer in this patient population. After an unprovoked VTE diagnosis, patients should undergo a thorough medical history, physical examination, basic laboratory investigations (ie, complete blood count and liver function tests), chest X-ray, as well as ageand gender-specific cancer screening (breast, cervical, colon, and prostate). More intensive cancer screening including additional investigations (eg, computed tomography of the abdomen/pelvis) does not seem to increase the rate of occult cancer detection, decrease cancer-related morbidity, or increase survival or cost-effectiveness.
| INTRODUCTION
Unprovoked venous thromboembolism (VTE) may be the first manifestation of an undiagnosed cancer. To potentially allow earlier cancer detection and treatment and ultimately reduce cancer-related mortality, it is appealing for clinicians to subject their patients to occult cancer screening. However, the degree of aggressiveness to which clinicians should screen for an occult cancer in such patients is an important clinical conundrum. Over the last decade, several studies have been performed to identify which screening strategy may provide the best diagnostic yield for occult cancer detection in this patient population.
We sought to review the past, underscore the present, and discuss the future of occult cancer detection in patients with unprovoked VTE.
| THE PAST
In order to counsel patients with unprovoked VTE on the risks and benefits of occult cancer screening, clinicians first require a precise estimate of the prevalence of occult cancer detection in this patient population. In 2008, a systematic review of 15 observational studies and RCTs reported that the 12-month period prevalence of occult
Essentials
• Unprovoked venous thromboembolism (VTE) may be the first manifestation of an undiagnosed cancer.
• The rate of occult cancer detection in patients with unprovoked VTE is approximately 5%.
• Clinicians should keep a low threshold of suspicion for occult cancer in these patients.
• Patients should only undergo a limited as well as age-and gender-specific cancer screening.
cancer detection in patients with unprovoked VTE was 10.0% (95% CI, 8.6-11.3%). 1 Given that approximately 1 in 10 patients with unpro- cancer-related morbidity. More importantly, the extensive occult cancer screening strategy performed in the SOMIT trial was exhaustive and unpractical for daily clinical practice. Therefore, a decision analysis using the trial's data was performed in order to guide clinicians on which of the diagnostic tests had the best yield for occult cancer de-
tection. An extensive screening strategy including a CT abdomen/pelvis seemed to be the best occult cancer screening strategy. 6 Similarly, a
2008 meta-analysis (n=4378 patients) also suggested that a CT abdo- physicians were suggested to consider a CT abdomen/pelvis, as well as mammography for women (see Figure 1 ). 7 
| THE PRESENT
The reported rates of occult cancer detection in patients with unprovoked VTE seem to have been decreasing significantly over time.
Recently published trials (see Table 1 ) assessing different strategies of occult cancer detection in this patient population have reported much lower overall rates of occult cancer detection (approximately 4-5%) within 12 months of follow-up. 8, 9 Similarly, a large prospective study reported a rate of occult cancer detection of 5% over a 30-months follow-up period. 10 Therefore, these new event rates should be reassuring for patients and clinicians. Nowadays, the risk of occult cancer detection in patients with unprovoked VTE seems to be approxi- 
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Van Doormaal et al. for certain types of tumors. A large case-control study suggested that although the risk of occult cancer was strongest within the first 12 months following VTE diagnosis, the risk remained elevated for up to 6 years for colon cancer, pancreatic cancer, and multiple myeloma. 11 Hence, long-term follow up focused on these cancers among patients with unprovoked VTE might be warranted.
Since the publication of the 2012 NICE recommendation, one prospective observational study and 3 large randomized controlled trials comparing the effectiveness of a limited vs an extensive screening strategy were completed and published. [8] [9] [10] 12 The Trousseau study compared an extensive occult screening strategy including a CT thorax/abdomen/pelvis for all patients and a mammography in women to a limited occult cancer screening in patients presenting with unprovoked VTE. Occult cancer was detected at enrolment in only 2.4%
of patients that underwent a limited screening strategy compared to 3.5% in those that underwent the extensive strategy. There was no difference in the number of occult cancers missed during follow-up or in the overall mortality. 10 In 2015, the Canadian Screening for Occult
Malignancy in Patients with Idiopathic Venous Thromboembolism
(SOME) randomized controlled trial (n=854) evaluated the efficacy and safety of adding a CT abdomen/pelvis to a limited screening strategy for occult cancer detection in patients with unprovoked VTE.
The study demonstrated that there was no significant difference in the primary outcome of the number of cancers missed by the limited or extensive occult cancer screening strategy (absolute difference of 0.25%; 95% CI, −1.12% to 1.63%). There was also no significant difference in the overall number of occult cancers detected, time to cancer diagnosis or reduction in cancer-associated death between the 2 strategies. 8 The findings of the SOME trial are consistent with another trial published in 2016. An Italian randomized controlled trial reported that a CT-based screening strategy did not provide any significant benefits compared to a more limited screening strategy for the detection of occult cancer (absolute difference, 2.0%; 95% CI −7.2 to 11.1, P=.81) among patients with unprovoked VTE. 12 The study also failed to demonstrate any reduction in overall and cancer-associated mortality. 12 Furthermore, a UK cohort study reported that none of the CT abdomen/pelvis done as per the 2012 NICE recommendations for occult cancer screening in patient with unprovoked VTE revealed any occult cancer over a median follow-up period of 22 months. 13 Finally, in 2017, an economic analysis demonstrated that the addition of a CT abdomen/pelvis to a limited screening strategy was not cost effective for the detection of occult cancer in this patient population. 14 Taken together, current evidence suggests that an extensive cancer screening strategy including a CT abdomen/pelvis does not appear to provide a significant benefit over a more limited approach. Additionally, a more intensive cancer screening strategy does not seem to provide value, and is associated with potential harms including stress, fear, anxiety, as well as excessive radiation exposure to patients. 15 Other diagnostic imaging modalities have been evaluated as potential additional investigations to include within an extensive occult cancer screening strategy. A large French trial randomized 394 patients with unprovoked VTE patients to undergo either limited occult cancer screening alone or in combination with fludeoxyglucose positron emission tomography (¹⁸F-FDG PET)/CT scan. In the primary outcome analysis, the study concluded that there is no significant difference in the rate of occult cancer detection between the two study groups (absolute risk difference 3.6%, 95% CI, −0.4 to 7.9, P=0.07). Similarly, an international clinical study assessing the diagnostic accuracy of platelet RNA profiling for occult cancer detection in patients with unprovoked VTE is currently ongoing (NCT02739867).
In summary, while awaiting validated tools to identify subsets of patients with unprovoked VTE who would benefit from extensive screening, patients should only undergo a thorough medical history, physical examination, basic laboratory investigations (ie, complete blood count and liver function tests), chest X-ray as well as age-and gender-specific cancer screening (breast, cervical, colon, and prostate).
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